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Abstract
Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease, which leads to the loss of
upper and lower motor neurons, with a currently unknown etiology. Specific biomarkers could help in early
detection and diagnosis, and could also act as indicators of disease progression and therapy effectiveness.
MicroRNAs (miRNAs) are small (18–25 nucleotides), single-stranded non-coding RNA molecules that play important
regulatory roles in animals and plants by targeting mRNAs for cleavage or translational repression, and are essential
for nervous system development. Many of the genes associated with genetic ALS have pathological biological
pathways related to RNA metabolism, and their pathogenesis may be affecting the maturing processes of miRNA.
Results: We compared miRNA from the plasma of sALS patients and healthy controls using two cohorts; a
discovery cohort analyzed with microarray (16 sALS patients and ten healthy controls) and a validation cohort
confirmed with qPCR (48 sALS patients, 47 healthy controls and 30 disease controls). We measured the total
amount of extracted RNA along with a spike-in control that ensured the quality of our quantification. A percentage
of the 10–40 nt RNAs extracted from the total RNA showed a significant increase in ALS patients. There was a
negative correlation between total RNA concentration and disease duration from onset to end point. Three of the
miRNAs were up-regulated and six were down-regulated significantly in the discovery cohort. Since an internal
control is required as a sample stability indicator of both the patients and controls in microarray analysis, we
selected the miRNA showing the smallest dispersion and equivalency between the two groups’ mean value, and
decided to use hsa-miR-4516. We found hsa-miR-4649-5p to be up-regulated, and hsa-miR-4299 to be down-regulated,
where each was not influenced by clinical characteristics. EPHA4, a target gene linked to the nervous system which has
also been reported to be a disease modifier of ALS, is the common and most notable target gene of hsa-miR-4649-5p
and hsa-miR-4299.
Conclusion: We have shown the relationship circulating plasma miRNA has with both healthy controls and diseased
patients. Hsa-miR-4649-5p and hsa-miR-4299 have the potential to be ALS diagnosis biomarkers.
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Background
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurode-
generative disease which leads to the loss of upper and
lower motor neurons, with a currently unknown patho-
genesis. Specific biomarkers could help in early detection
and diagnosis, and could also act as indicators of disease
progression and therapy effectiveness. Numerous bio-
marker candidates have emerged, but none have been
directly linked to the cause of ALS.
MicroRNAs (miRNAs) are small (18–25 nucleotides),
single-stranded, non-coding RNA molecules that play
important regulatory roles in animals and plants by target-
ing mRNAs for cleavage or translational repression [1].
Each miRNA is estimated to regulate around 200 targets,
and mRNA transcripts may be regulated by multiple miR-
NAs [2, 3]. RNA polymerase II transcribes pri-miRNA
from the miRNA gene, and Drosha, RNase III enzyme and
its binding partner DGCR8 process pri-miRNA into hair-
pin structures called pre-miRNA [4]. The pre-miRNAs are
then exported by Exportin 5 into the cytoplasm, where a
second RNase III enzyme Dicer cleaves the pre-miRNA to
generate double-stranded miRNA duplexes. Further, these
duplexes are bound with Argonaute 2 (AGO2), an import-
ant component of the RNA-induced silencing complex,
and are selected to be mature miRNAs [5]. MiRNAs play
an important role in nervous system development [6, 7].
Haramati et al. found that disturbing the miRNA biogen-
esis pathway by deleting Dicer from spinal motor neurons
in mice caused a Spinal Muscular Atrophy (SMA) like
phenotype [8]. MiRNA expression and its role in neuronal
diseases including amyotrophic lateral sclerosis have been
suggested, but specifics are yet to be understood [9–14].
MiRNAs are found in biological fluids such as blood,
urine and cerebrospinal fluid (CSF) and are said to be
stable because they are encapsulated in exosomes or
found in complexes with Argonaute proteins and lipo-
proteins which make them resistant to RNase present in
the circulating environment [15–17]. In our study, we
compared miRNA from the plasma of sALS patients
with healthy controls using two cohorts; a discovery co-
hort analyzed with microarray and a validation cohort




There were 16 sALS patients and ten healthy controls in
the miRNA microarray discovery cohort, and 48 patients
and 77 controls (47 healthy and 30 disease (Parkinson’s))
in the reverse transcription-quantitative polymerase
chain reaction (RT-qPCR) validation cohort. The num-
ber of subjects and patient’s characteristics are provided
in Table 1. The patients and controls of each cohort did
not overlap. Although there were a variety of individuals
in the discovery cohort, there were no significant gender
or age biases between the groups in the validation co-
hort. Seven sALS patients of the validation cohort pro-
vided their blood two or more times (four at most), and
samples were taken at six or 12 month intervals. The
samples collected a second time and later were used
only for time duration studies which are described later
and were not included in the validation cohort.
Quantification and analysis of the total RNA extracted
from plasma
The RNA extracted from the validation cohort was im-
mediately quantified using a Bioanalyzer 2100. Among
the miRNA of sALS patients, only the very small RNA
Table 1 General and clinical characteristics of the study subjects respective of cohort
Type of cohort Discovery cohort (N = 26) Validation cohort (N = 95)
Patients’ characteristics sALS patients (n = 16) Controls (n = 10) sALS patients (n = 48) Healthy controls (n = 47) Disease controls (n = 30)
Age (mean ± SD) 65.62 ± 9.11 49.30 ± 14.88 66.67 ± 10.52 67.08 ± 10.89 69.00 ± 5.91
Gender (n) Male 9 5 29 29 17
Females 7 5 19 18 13
Disease duration from onset to
collection, months (mean ± SD)
17.18 ± 9.29 20.04 ± 18.43
Initial symptoms (n) Bulbar 3 20
Upper limb 10 17
Lower limb 3 11
ALSFRS-R (mean ± SD) 36.06 ± 10.59 33.15 ± 11.72
Bulbar paralysis scores of
ALSFRS-R (mean ± SD)
9,75 ± 3.51 8.06 ± 4.04
Barthel Index (mean ± SD) 72.19 ± 31.99 68.02 ± 34.23
Disease duration from onset to
end point, months (mean ± SD)
31.00 ± 13.66 28.58 ± 18.72
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(10–40 nt) group had a significant increase (Fig. 1a). In a
multivariable analysis that included clinical characteris-
tics, the total RNA concentration and disease duration
from onset to end point showed a negative correlation
(r = −0.385, p = 0.0267*) (Fig. 1b).
Differential expression of plasma miRNA in ALS patients
compared with healthy controls using microarray
Using the 3D-Gene microarray system, we were able to
quantify 1800 total human miRNAs in the discovery co-
hort. Three of the sufficiently detected miRNAs were
up-regulated in sALS patients’ plasma (Table 2). 120 of
the miRNAs were significantly down-regulated in ALS
patients. We selected only the top 6 miRNAs showing a
fold change of less than 0.5, but also, sufficient expres-
sion in healthy controls’ plasma (hsa-miR-26b-5p, hsa-
miR-4299, hsa-let-7f-5p, hsa-miR-4419a, hsa-miR-3187-
5p and hsa-miR-4496) (Table 2).
The miRNAs that were found to be significantly
expressed were multivariable-analyzed along with clin-
ical characteristics. Up-regulated miRNAs hsa-miR-663b
and hsa-miR-4649-5p showed a negative correlation with
disease duration from onset to end point (hsa-miR-663b;
r = −0.612, p = 0.0263*, hsa-miR-4649-5p; r = −0.732,
p = 0.0045*)
Since in RT-qPCR analysis an internal control is re-
quired as a sample and PCR stability indicator, we se-
lected the miRNA showing the smallest dispersion and
equivalency between the two groups’ mean value, and
decided to use hsa-miR-4516.
Validation analysis using RT-qPCR
To ensure sample quality and sufficient extraction
amounts, we calculated the return rate with a spike-in
control (cel-miR-39-3p), which was found sufficiently in
every sample. Hsa-miR-4516 was the most stable when
relative quantification normalized with an internal con-
trol was used, so we decided to use this as the internal
control.
Hsa-miR-4649-5p was confirmed as being significantly
up-regulated (relative expression; 1.532, p = 0.0009*) in
the plasma of ALS patients. There were no significant
differences between ALS patients and normal controls
for hsa-miR-4258 and hsa-miR-663b (Table 3). Hsa-miR-
4299 was significantly down-regulated in the plasma of
ALS patients in both of the normalization methods
(relative expression; 0.026, p = 0.0001*), Hsa-miR-26b-5p
did not have a significant expression change. Unfortu-
nately, the analysis of three miRNAs (hsa-miR-4419a,
hsa-miR-3187-5p, hsa-miR-4496) failed because they
formed nonspecific primer dimers. A comparison of
each parameter with the Receiver Operating Characteris-
tic (ROC) curve showed that hsa-miR-4649-5p and hsa-
miR-4299 showed a high area under the curve (AUC)
value (hsa-miR-4649-5p; AUC = 0.696, hsa-miR-4299;
AUC = 0.728) (Fig. 2a, b). Hsa-miR-4649-5p and hsa-
miR-4299 didn’t show any significant differences with
Parkinson’s disease (PD) patients and controls, but hsa-
miR-663b was found to be up-regulated in PD patients
(relative expression; 1.328, p = 0.0094*) (Table 4).
When miRNAs were analyzed against clinical charac-
teristics, hsa-let-7f-5p and bulbar paralysis scores of the
ALS Functional Rating Scale revised (ALSFRS-R)
showed a negative correlation (r = −0.478, p = 0.0006*
(Fig. 2c). Hsa-let-7f-5p was found to be especially de-
creased in patients whose initial symptoms appeared as
spinal-onset (p = 0.0017*)(Fig. 2d). The other miRNAs
seemed to not be influenced by clinical characteristics.
Hsa-miR-4649-5p did not show a negative correlation
with disease duration from onset to end point.
Fig. 1 The concentration of extracted plasma RNA. a Percentages of 10-40 nt RNA including miRNA that were significantly increased in ALS
(p = 0.0002*). b A scatterplot of disease duration from onset to end point and total RNA concentration, showing a negative correlation
(r = −0.385, p = 0.0267*)
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Hsa-miR-663b increased over time in individual patients
A follow-up collection was possible with seven of the pa-
tients in the validation cohort, where the longest follow-
ing of a patient was 24 months. There wasn’t a
significant difference in hsa-miR-663b when comparing
sALS patients and healthy controls, but there was a ten-
dency to increase over time for this miRNA (Fig. 3). We
confirmed the magnitude of increase with copy num-
bers, calculated using total RNA concentration and a
spike-in-control (cel-miR-39-3p) (Additional file 1). The
other miRNAs did not show a clear trend.
Discussion
We have presented a study showing the potential of cir-
culating cell-free miRNAs to be disease biomarkers in
sALS, using two different methods. Significantly
expressed miRNAs in a discovery cohort using micro-
array analysis were confirmed as being either up- or
down-regulated with a validation cohort using RT-qPCR,
a methodology completely different from microarray.
When determining the quantity of miRNA in a circu-
lating environment, there are several points to consider.
Firstly the housekeeping gene is not fixed unlike those in
the intercellular environment. Secondly, because of the
small molecular weight of the miRNA, a comparison
with a spike-in control requires the concentration of the
control be adjusted accordingly. Finally, to do a simple
comparison between a miRNA and a spike-in-control, it
is understood that the miRNA amounts in each are
equal. This is because the normalization method of
microarray is based on the assumption that concentra-
tions of the subjects are equal. Microarray systems usu-
ally analyze whole species of miRNA, hence with thinner
miRNA which were close to the lower limit of lumi-
nance detection, their up- or down-regulation may not
be satisfactorily detected. We think that the miRNAs
showing a common expression in both cohorts are the
most suitable biomarker candidates. Quantifying the
total extracted RNA and spike-in-control (cel-miR-39-
3p) gave us confidence in our sample quality and reas-
sured us of our quantification method. RT-qPCR results
were analyzed using relative quantification with an in-
ternal control. We used hsa-miR-4516 as the internal
control because it had the most stable expression, smal-
lest dispersion and equivalency between the two groups’
mean value.
In the comprehensive microarray analysis, up-
regulated miRNAs were rare but miRNAs that were sig-
nificantly down- regulated were abundant, about 120.
We narrowed our potential biomarker candidate miR-
NAs to the top six which showed a fold change of less
than 0.5 because the amount of RNA that was extracted
restricted the number of miRNAs that could be analyzed
with RT-qPCR.
Many of the genes associated with genetic ALS have
pathological biological processes / pathways related to
RNA processing, and especially proteins belonging to
hnRNP classes were reported to participate in the path-
ology of ALS (TARDBP and FUS) [18]. ALS pathogen-
esis may be affecting the synthesis and maturing
Table 2 Up- or down- regulated miRNAs using microarray analysis and extraction of an internal control
Differential expression type MiRNA name Fold
change
p value
Student t-test Wilcoxon sum ranked test
Up-regulated hsa-miR-4258 1.109 <0.0001* 0.0001*
hsa-miR-663b 1.117 0.0004* 0.0017*
hsa-miR-4649-5p 1.045 0.0659 0.179
Down-regulated hsa-miR-26b-5p 0.374 <0.0001* 0.0001*
hsa-miR-4299 0.435 0.0001* 0.0006*
hsa-let-7f-5p 0.464 <0.0001* 0.0002*
hsa-miR-4419a 0.464 0.0001* 0.0002*
hsa-miR-3187-5p 0.485 0.0002* 0.0001*
hsa-miR-4496 0.495 0.0003* 0.0011*
Candidates of Internal control hsa-miR-4516 0.999 0.9340
*p < 0.05
Table 3 The comparison of up- or down- regulated miRNAs
between ALS and healthy controls using qPCR
differential
expression type
MiRNA name Relative expressiona p value
Up-regulated hsa-miR-4258 0.990 0.4605
hsa-miR-663b 1.090 0.9935
hsa-miR-4649-5p 1.532 0.0009*




aAverage of the expression level of internal control (hsa-miR-4516) = 1
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processes of miRNA. It has been reported that TDP-43
(43-kDa TAR DNA-binding protein, TARDBP) cooper-
ates with other microprocessors such as Drosha and
Dicer to promote miRNA biogenesis [19]. The resulting
distribution difference of the extracted RNA may be il-
lustrating a failure of a RNA metabolism mechanism.
We found that the 10-40 nt RNA group increased sig-
nificantly, but only a few of the miRNAs were up-
regulated. There are some hypotheses for this
phenomenon; there may be unknown or de novo
miRNA in the plasma of ALS patients, or there may be
small, functional or non-functional RNA other than
miRNA that may be being spliced and secreted abnor-
mally resulting in inadequate RNA metabolism in ALS
pathogenesis.
Previously, it was reported that hsa-miR-338-3p was
up-regulated in ALS patients’ blood leukocyte, serum,
CSF, and spinal cord and hsa-miR-1234-3p and hsa-miR-
1825 were down- regulated in ALS patients’ serum [10,
11]. Our analysis showed that hsa-miR-338-3p was not
significantly up-regulated (fold change 0.622; p-value of
student’s t test; 0.112) and the mean value was relatively
low within the discovery cohort (median of all miRNAs’
expression level; 25, hsa-miR-338-3p; 22.7). The compre-
hensive analysis of the previous report consisted of ana-
lyzing samples extracted from leukocytes while they
verified their individual miRNAs using qPCR with sam-
ples extracted from serum. Additionaly, our analysis
showed hsa-miR-1234-3p was down-regulated and hsa-
miR-1825 was significantly down-regulated in ALS pa-
tients’ plasma (fold change; 0.665, p value of student’s t
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Fig. 2 The miRNAs significantly expressed in the validation cohort. a The ROC curve of hsa-miR-4649-5p and ALS/control, where the AUC value
was 0.696. b The ROC curve of hsa-miR-4299 and ALS/control, where the AUC value was 0.728. c The negative correlation of hsa-let-7f-5p with
bulbar paralysis scores of ALSFRS-R. d Showing hsa-let-7f-5p as decreasing more in spinal-onset patients than in non-spinal-onset patients
Table 4 The comparison of up- or down- regulated miRNAs
between PD and healthy controls using qPCR
differential
expression type
MiRNA name Relative expressiona p value
Up-regulated hsa-miR-4258 0.753 0.1197
hsa-miR-663b 1.328 0.0094*
hsa-miR-4649-5p 0.927 0.2498




aAverage of the expression level of internal control (hsa-miR-4516) = 1
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for the fold change, we decided not to further analyze
these miRNA.
Hsa-miR-4649-5p was up-regulated in both microarray
analysis and RT-qPCR. It did not show a statistically sig-
nificant difference in microarray but showed a strong
negative correlation with disease duration from onset to
end point in the validation cohort. We had high expecta-
tions for it to be a biomarker candidate so proceeded
with the analysis of qPCR even though microarray re-
sults were not statistically significant. P values of the
Student’s t test depend on the difference and number of
the samples. Regretfully, recruiting similar aged controls
and increasing the number of samples may have lead to
similar results in both cohorts. This miRNA is tran-
scribed from the 12th intron of AEBP1, chr7 [20], where
the AEBP1 protein is estimated to function as a tran-
scriptional repressor and play a role in adipogenesis and
smooth muscle cell differentiation and is expressed in
the brain. Gene Ontology (GO) analysis using MetaCore™
(https://portal.genego.com, Thomson Reuters Inc,.
Carlsbad, CA) revealed that the top group of target
genes for hsa-miR-4649-5p predicted by miRmap
(mirmap.ezlab.org) has process networks for cytoplas-
mic microtubles, integrin-mediated cell-matrix adhe-
sion and axonal guidance (Additional files 2 and 3).
Their GO processes are protein assembly and biogen-
esis, regulation of astrocyte differentiation, neuron rec-
ognition, axonogenesis and central nervous system
neuron development (Additional file 4).
Hsa-miR-663b was up-regulated in the plasma of PD
patients in microarray analysis and showed an increase
over time. It is present in chr2, not an intragenic
miRNA, and also highly expressed in the brain. An ana-
lysis of biological systems revealed that their target genes
are linked to the process networks of neurogenesis,
transmission of nerve impulses and positive regulation
cell proliferation (Additional files 2 and 3). Their GO
process are activating or inhibiting dopamine and
adrenergic receptor signaling pathways and nervous sys-
tem neuron development (Additional file 4). The in-
crease in hsa-miR-663b may suggest an acceleration of
damage to the neuron in the latter stages of ALS.
Both hsa-miR-4649-5p and hsa-miR-663b showed a
negative correlation with disease duration from onset to
end point in microarray analysis. There was no correl-
ation seen in qPCR analysis, but the total RNA concen-
tration of these miRNA showed a negative correlation
with disease duration from onset to end point. This may
be a result of the microarray analysis methodology
which requires the use of two duplicate reactions for
every one sample of extracted RNA, which may inevit-
ably contribute to the concentration of total RNA being
different in the two reactions.
Hsa-let-7f-5p is one of the let-7 family members con-
firmed to be in a wide range of species. It is expressed
highly in a lot of organs including the brain and is not
an intragenic miRNA. Biological systems analysis reveals
that their target genes are linked to the process networks
of protein folding, mitosis, and cell adhesion (Additional
files 2 and 3). Their GO process is said to be positive
regulation of smooth muscle cell chemotaxis (Additional
file 4). Hsa-let-7f-5p was down-regulated, especially in
spinal-onset patients. This finding combined with the
finding of a negative correlation between this miRNA
and ALSFRS-R bulbar paralysis score (less is worse) may
indicate a link between this miRNA and amount of
muscle volume present in a patient. The percentage of
spinal-onset patients was high in the discovery cohort
(81 %) which may have lead to not seeing a significant
difference in qPCR.
Hsa-miR-4299 is transcribed from chr11, and is not an
intragenic miRNA. An analysis of biological systems re-
vealed that their target genes are linked to the process net-
works of cell adhesion, regulation of angiogenesis, and
axonal guidance (Additional files 2 and 3). Their GO pro-









































Fig. 3 Hsa-miR-663b increased in the time course. The seven patients we were able to follow over time, and hsa-miR-663b showing an increase
over time. Relative expressions are shown as the first collection standard
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structure and activity, positive regulation of dense core
granule biogenesis and central nervous system neuron de-
velopment (Additional file 3). Hsa-miR-4299 was signifi-
cantly down-regulated in both microarray analysis and
qRT-PCR. The down-regulation we saw contradicts an
ALS patients’ FFPE (formalin-fixed paraffin embedded)
sample study which revealed that within 364 miRNAs in
the motor cortex, 91 were up-regulated and 233 were
down- regulated, and hsa-miR-4299 was notably up-
regulated [21]. The FFPE sample study used neural, glial
and endothelial cells and is considered to be a reflection
of intracellular miRNAs. Plasma miRNAs are secreted
from the cell and circulate, hence, the contradictive ex-
pression of hsa-miR-4299 may be explained by the intra-
or extracellular conditions. There are some possible expla-
nations for this phenomenon; there is a compensatory re-
action in the neural cells which modify ALS progress, or
there is a pathological mechanism change in the secreting
of miRNAs.
There are some commonly predicted target genes for
some of the miRNAs, and according to miRmap, EPHA4
is the most common and notable target gene of hsa-
miR-4649-5p and hsa-miR-4299 (Additional file 2).
EPHA4 has been reported to be highly expressed in ani-
mal models and humans, and is said to be a disease
modifier of ALS. Its expression inversely correlates with
disease onset and survival, and its knockdown rescues
the axonopathy induced by expression of mutant
TARDBP and SMN [22]. Up-regulated hsa-miR-4649-5p
and hsa-miR-4299 are predicted to down-regulate
EPHA4, and is surmised as being a compensating mech-
anism for neuronal death. But, on the other hand, a dra-
matic down-regulation of hsa-miR-4299 in plasma could
be a possible factor for deterioration. In the future, an
intervention of miRNAs which regulate disease modifier
genes could in turn, moderate the progress of ALS.
Conclusion
We have shown the relationship circulating plasma
miRNA has, with both disease patients and healthy
controls. Hsa-miR-4649-5p showed up-regulation and
hsa-miR-4299 showed down-regulation regardless of
measurement methodology, and they have the potential to
be ALS diagnosis biomarkers.
Materials and methods
Patients and participants
Sixteen sALS patients and ten healthy controls from
Hokkaido University Hospital sampled Aug 2008 ~ Sep
2012 were included in the discovery cohort. For the val-
idation cohort, 48 other sALS patients and 47 other
healthy controls from Hokkaido University Hospital and
Obihiro Kosei General Hospital sampled Oct 2009 ~ Sep
2013 were included. All sALS patients were diagnosed
by board-certified neurologists as being at least clinically
possible under the El Escorial and Airlie House diagnos-
tic criteria [23]. Patients expressing only an upper or
lower motor deficiency or presenting with coexisting
neurological disorders were excluded. All participants
did not have other serious diseases or infections of hepa-
titis B virus (HBV), hepatitis C virus (HCV), human im-
munodeficiency virus (HIV) or human T-cell leukemia
virus type 1 (HTLV-I). The C9ORF72 mutation of famil-
ial ALS was excluded in all sALS patients. As part of the
scale assessment, each of the sALS patient’s clinical
demographics; age at time of collection, sex, disease dur-
ation from onset to collection and onset to end point,
initial symptoms, ALSFRS-R [24], bulbar paralysis scores
of ALSFRS-R, and Barthel Index were noted [25]. The
patient’s date of death or start date of invasive mechan-
ical ventilation was set as the end point of the observa-
tion. Further, for every traceable patient, we noted in
detail the disease duration from onset to end point. We
were able to collect and analyze twice for seven of the
patients in the validation cohort.
We received consent forms from all participants in the
study, and the study was approved by the Ethical
Standards Committee of both institutions.
Sample preparation and microarray analysis
Blood was collected in disodium ethylenediaminotetraa-
cetate (Na2EDTA) tubes and centrifuged immediately,
after which the plasma was separated and frozen at
−80 °C. RNA (total RNA) was extracted from 300 μl of
the frozen plasma using a 3D-Gene® RNA extraction re-
agent (TORAY Industries, Inc., Tokyo, Japan) and the
half of the extracted product was used. After being la-
beled with an Exiqon miRCURY LNA™ microRNA Array
Power Labeling kit (Exiqon Inc., Woburn, MA, USA),
miRNAs were analyzed with a 3D-Gene® Human miRNA
oligo chip (Ver. 17.0) (TORAY Industries, Inc., Tokyo,
Japan) which carries approximately 1800 probes to de-
tect human miRNAs using fluorescent signals. From the
outputted signal data, we subtracted the background
noise, and calibrated using the global normalization
method with the median value as 25.
Comparisons of all normalized miRNA data calculated
as a binary logarithm underwent a paired t test, Wilcoxon
rank sum test, fold change ratio and variance using JMP®
Pro 11.0.0. (SAS Institute Inc., Cary, North Carolina,
USA). MiRNA showing the most significant changes
either up-regulating or down-regulating in sALS patients,
were chosen as the biomarker candidates for validation
analysis.
Validation of miRNAs with RT-qPCR
The total RNA was extracted from frozen plasma
(200 μl) using a miRNeasy Serum/Plasma Kit (QIAGEN
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Inc., Valencia, CA, USA). C.elegans miR-39-3p (Cel-
miR-39-3p) synthetic oligonucleotide RNA (Sigma-
Aldrich, Saint Louis, Missouri, USA) (400amol), used
as a spike-in control was added to the plasma after
the addition of a denaturing solution.
The concentration of the extracted RNA was mea-
sured using Bioanalyzer 2100 with an Agilent RNA 6000
pico kit and Agilent small RNA kit (Agilent Technology
Inc., Urdorf, Switzerland). For cDNA synthesis, 1 ng of
total RNA was reverse calculated from the concentration
and was reverse transcribed in a 20 μl reaction using a
miScript II RT kit (QIAGEN Inc., Valencia, CA, USA).
A miScript SYBR® Green PCR Kit (QIAGEN Inc.,
Valencia, CA, USA) and miScript Primer Assays (QIA-
GEN Inc., Valencia, CA, USA) were used on a Applied
Biosystems® StepOnePlusTM real time PCR system (Ap-
plied Biosystems, Foster City, CA, USA) to quantify the
plasma miRNAs. There were 11 Qiagen miScript
primers used: hsa-miR-4258, hsa-miR-663b, hsa-miR-
4649-5p, hsa-miR-26b-5p, hsa-miR-4299, hsa-let-7f-5p,
hsa-miR-4419a, hsa-miR-3187-5p, hsa-miR-4496, cel-
miR-39-3p and hsa-miR-4516. Hsa-miR-4516 was used
as an internal control because it showed minimum vari-
ance and approximation value between the controls and
patients in miRNA microarray analysis. Run in duplicate
25 μl reactions, comparative quantification was used to
determine the relative quantities of miRNA from hsa-
miR-4516. Each of the comparative quantification
values, along with the clinical characteristics were ana-
lyzed with Student’s -t test, receiver operating character-
istic curve and Pearson product–moment correlation
coefficient using JMP® Pro 11.0.0. A P value less than
0.05 (*) was considered statistically significant.
Additional files
Additional file 1: Calculated copy numbers of hsa-miR-663b
showed increases over time. (PDF 30 kb)
Additional file 2: The most predictable target genes found by
miRmap. (CSV 1 kb)
Additional file 3: Results of process network analysis from
Metacore™. (CSV 2 kb)
Additional file 4: Results of Gene Ontology analysis from
Metacore™. (CSV 2 kb)
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